Demystify Meds for Moderate to Severe Crohn’s Disease

August 2023

We’re getting questions about how to manage moderate to severe Crohn’s disease...due to a new indication for upadacitinib (Rinvoq).

Continue to use shared-decision making and lean toward a “top-down” approach...with earlier use of biologics before steroid dependence or disease progression. And work closely with GI colleagues.

Biologics include TNF-alpha blockers (adalimumab, etc)...anti-interleukin meds (ustekinumab, etc)...and selective adhesion blockers (vedolizumab, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology Match Antithrombotics With Type of Prosthetic Heart Valve
Infectious Diseases Expect Buzz About Vowst, a New Oral Fecal Microbiota Product
Geriatrics Stay Updated on the New Beers Criteria Guidelines
Pneumonia Know the Role of Steroids for Community-Acquired Pneumonia
Med Safety Help Ensure Appropriate Use of Stimulants
Testosterone Put CV Risks With Testosterone in Perspective
Opioids Use a Stepwise Approach When Converting Opioids
Crohn's Disease Demystify Meds for Moderate to Severe Crohn’s Disease
NatMed Spotlight Be Prepared With Answers About Milk Thistle

Demystify Meds for Moderate to Severe Crohn’s Disease

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents